Figure 1.
VWF concentrate (Humate-P) dosing and ristocetin cofactor activity response in 3 patients with aVWD. (A) Patient 1’s treatment course during second admission; (B) patient 2’s treatment course; and (C) patient 3’s treatment course.
VWF concentrate (Humate-P) dosing and ristocetin cofactor activity response in 3 patients with aVWD. (A) Patient 1’s treatment course during second admission; (B) patient 2’s treatment course; and (C) patient 3’s treatment course.